AI Engines For more Details: Perplexityβ Kagi Labsβ Youβ
Depression: Pirlindole mesylate is indicated for the treatment of depression, including major depressive disorder (MDD). It works by inhibiting the enzyme monoamine oxidase A (MAO-A), which increases the levels of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain. By enhancing neurotransmitter activity, pirlindole mesylate helps alleviate depressive symptoms such as low mood, loss of interest or pleasure, fatigue, changes in appetite, and sleep disturbances.
Monoamine Oxidase Inhibition: As a reversible inhibitor of MAO-A, pirlindole mesylate selectively and reversibly blocks the breakdown of monoamine neurotransmitters in the brain. This mechanism of action differs from that of traditional monoamine oxidase inhibitors (MAOIs), which irreversibly inhibit MAO enzymes and require dietary restrictions due to the risk of tyramine-induced hypertensive crisis.
Symptom Improvement: Pirlindole mesylate treatment has been shown to lead to improvements in mood, energy levels, motivation, concentration, and overall functioning in individuals with depression. It may also help reduce feelings of anxiety and agitation associated with depressive disorders.
Onset of Action: Pirlindole mesylate typically exhibits a relatively rapid onset of action compared to some other antidepressant medications. Some patients may experience symptom relief within a few weeks of starting treatment, although full therapeutic effects may take several weeks to manifest.
Side Effects: Common side effects associated with pirlindole mesylate therapy may include dizziness, drowsiness, headache, nausea, dry mouth, constipation, blurred vision, and sexual dysfunction. Most side effects are mild to moderate in severity and tend to improve over time. However, individuals experiencing severe or persistent side effects should consult their healthcare provider.
Cardiovascular Effects: Pirlindole mesylate has a favorable side effect profile in terms of cardiovascular safety compared to older MAOIs. It generally does not significantly affect blood pressure or heart rate and is less likely to cause orthostatic hypotension or hypertensive crises associated with dietary tyramine intake.
Liver Function Monitoring: Patients taking pirlindole mesylate should undergo periodic monitoring of liver function tests, as rare cases of liver toxicity have been reported with its use. If signs of liver dysfunction such as jaundice, abdominal pain, or unexplained fatigue occur, medical attention should be sought promptly.
Contraindications: Pirlindole mesylate is contraindicated in individuals with a history of hypersensitivity to the drug, severe liver impairment, pheochromocytoma, and concurrent use of other MAOIs or certain medications metabolized by MAO enzymes. It should not be used concomitantly with serotonergic agents due to the risk of serotonin syndrome.
Drug Interactions: Pirlindole mesylate may interact with other medications, including antidepressants, sympathomimetic agents, antihypertensive drugs, and certain herbal supplements. Healthcare providers should review the patient's medication regimen carefully to avoid potential drug interactions.
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive β X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. β Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA β Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. β Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. β Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]